Ipsen Lifts 2026 Forecast After 20% Revenue Growth in First Half

French biopharmaceutical company Ipsen raised its full-year 2026 guidance after reporting a significant 20.4% increase in first-half revenue, driven by strong performance across its product portfolio. The results substantially exceeded analyst expectations, signaling robust momentum for the company.

First-Half Results Exceed Expectations

Ipsen announced first-half revenue of €2.19 billion, a stark increase from the same period last year and well above the consensus estimate of €1.56 billion compiled from two analysts. The company attributed the sales growth to its portfolio beyond Somatuline, with contributions from all three of its therapeutic areas.

Profitability also saw a substantial rise. Adjusted EBIT for the period reached €844.90 million, a 28.8% year-over-year increase that surpassed the €721 million estimate from one analyst. Other key financial metrics for the first half include:

• Core Operating Margin: Expanded by 2.5 percentage points to 38.6%.
• Adjusted Earnings Per Share (EPS): €7.33.
• Reported EPS: €4.86.

Upgraded Full-Year Guidance

Ad

Based on the strong first-half performance, Ipsen lifted its financial outlook for the full year 2026. The company now projects total sales growth to be above 20% at constant exchange rates, an upgrade from its previous forecast.

The core operating margin outlook was also raised and is now expected to be above 37% of total sales. Ipsen noted that it anticipates an approximately 1% adverse currency impact on 2026 total sales, based on exchange rates as of June.

Pipeline and Acquisitions Bolster Outlook

Ipsen's confidence is supported by positive developments in its clinical pipeline. The company highlighted successful Phase III trial results for Dysport in migraine treatment and for Iqirvo in primary biliary cholangitis, both of which support its future growth trajectory.

Furthermore, recent and proposed acquisitions of Memo Therapeutics AG and Kartos Therapeutics are set to add late-stage assets to the company’s development portfolio. These strategic moves are aimed at strengthening Ipsen's pipeline and sustaining long-term growth.